Managing oral phosphate binder medication expenditures within the medicare bundled end-stage renal disease prospective payment system: Economic implications for large U.S. dialysis organizations

Journal of Managed Care Pharmacy

Volumn 21, Issue 6, 2015, Pages 507-514

  Park, Haesuk ^a   Rascati, Karen L ^b   Keith, Michael S ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; CINACALCET; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; CHELATING AGENT; PHOSPHATE;

ARTICLE; DRUG COST; END STAGE RENAL DISEASE; HEALTH CARE QUALITY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; PERITONEAL DIALYSIS; PROSPECTIVE PAYMENT; REIMBURSEMENT; RENAL REPLACEMENT THERAPY; UNITED STATES; DIALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH ECONOMICS; TREATMENT OUTCOME; BLOOD; BUDGET; ECONOMICS; KIDNEY FAILURE, CHRONIC; ORAL DRUG ADMINISTRATION; PROCEDURES; STATISTICAL MODEL;

ADMINISTRATION, ORAL; BUDGETS; CHELATING AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; MODELS, ECONOMIC; PHOSPHATES; PROSPECTIVE PAYMENT SYSTEM; QUALITY OF HEALTH CARE; RENAL DIALYSIS; UNITED STATES;

EID: 84930364912     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.6.507     Document Type: Article

References (25)

1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-28.
2. Achinger SA, JC Ayus. Left ventricular hypertrophy: is hyperphosphatemia a risk factor in dialysis patients? J Am Soc Nephrol. 2006;17(12 Suppl 3):S255-61.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18.
4. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-202.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76:S1-2.
6. St Peter WL. Chronic kidney disease and Medicare. J Manag Care Pharm. 2007;13(9 Suppl D):S13-18. Available at: http://www.amcp.org/data/jmcp/JMCPSupp%20D_Dec07_S13-S18.pdf.
7. U.S. Renal Data System. USRDS 2012 annual data report: atlas of chronic kdney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012. Available at: http://www.usrds.org/atlas12. aspx. Accessed April 22, 2015.
8. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services. Medicare program; end-stage renal disease prospective payment system. Fed Regist. 2014;79(133):40208-315.
9. Winkelmayer WC. Potential effects of the new Medicare prospective payment system on drug prescription in end-stage renal disease care. Blood Purification 2011;31(1-3):66-69.
10. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist. 2010;75(155):49029-214.
11. Feldman R, Desmarais M, Muller J. Orals in the bundle: a policy framework. Clin J Am Soc Nephrol. 2013;8(6):1043-47.
12. U.S. House of Representatives. Summary of health provisions in the protecting access to Medicare Act of 2014. March 2014. Available at: http://democrats. energycommerce.house.gov/sites/default/files/documents/Summary-HR-4302-SGR-Medicare-2014-3-26.pdf. Accessed April 22, 2015.
13. Johnson DS, Meyer KB, Johnson HK. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization. Am J Kidney Dis. 2011;57(4):553-55.
14. Iglehart JK. Bundled payment for ESRD-including ESAs in Medicare's dialysis package. N Engl J Med. 2011;364(7):593-95.
15. Robinson B, Fuller D, Zinsser D, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011;57(6):822-31.
16. Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. Am J Kidney Dis. 2012;60(2):280-87.
17. Brunelli SM, Monda KL, Burkart JM, et al. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis. 2013;61(6):947-56.
18. OXERA. Fundamental review of the generic drugs market. U.S. Department of Health. July 2001. Available at: http://www.oxera.com/Oxera/media/Oxera/downloads/reports/Fundamental-review-of-generic-drugsindustry. pdf?ext=.pdf. Accessed April 22, 2015.
19. Sullivan JD. In a bundling era, finding a fair price for ESRD services. Nephrol News Issues. 2007;21(4):37, 39-40.
20. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22(10):2867-78.
21. Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24(2):601-08.
22. Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with endstage renal disease: a U.S. payer perspective. Value Health. 2011;14(8):1002-09.
23. Chiu YW, Teitelbaum I, Misra M, De Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-96.
24. Hutchinson AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(10):578-89.
25. Qunibi WY, Moustafa M, Kessler P, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65(5):1914-26.